Eikon Therapeutics Showcases Oblique Line Scan Tech in Nature Method
Eikon Therapeutics Showcases Oblique Line Scan Tech in Nature Method Eikon Therapeutics, Inc., a clinical-stage biotechnology company that integrates advanced engineering with cutting-edge molecular and cell biology to accelerate drug…
Lantern Pharma Publishes PCT Patent for AI Model Predicting BBB Permeability
Lantern Pharma Publishes PCT Patent for AI Model Predicting BBB Permeability Lantern Pharma Inc. (NASDAQ: LTRN), a leading artificial intelligence (AI) company dedicated to advancing cancer therapies and transforming the…
Ventus Therapeutics Names Dr. Mona Kotecha as Chief Medical Officer
Ventus Therapeutics Names Dr. Mona Kotecha as Chief Medical Officer Ventus Therapeutics, a clinical-stage biopharmaceutical company, has announced the appointment of Mona Kotecha, M.D., as its new Chief Medical Officer…
Alzamend Neuro Completes Tesla Head Coil for Phase II Trials at MGH
Alzamend Neuro Advances Alzheimer’s and Psychiatric Disorder Research with Tesla-Developed Head Coil for Phase II Trials Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company dedicated to developing innovative…
Celerion Expands UK Phase 1 Trials at Queen’s University Belfast’s iREACH Health
Celerion Expands UK Phase 1 Trials at Queen’s University Belfast’s iREACH Health Celerion, a global leader in early clinical research, has announced a strategic agreement to relocate its U.K. Phase…
Stablepharma Awarded €2.5M EIC Accelerator Grant, Named Among Europe’s Top 71 Innovators
Stablepharma Secures Prestigious €2.5 Million EIC Accelerator Grant, Recognised Among Europe’s Leading Innovators UK-based biotechnology company Stablepharma Ltd has secured €2.5 million in funding from the highly competitive European Innovation…
Precision BioSciences Reports Initial Safety and Antiviral Activity Data for PBGENE-HBV in the ELIMINATE-B Trial
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage gene editing company leveraging its proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet needs, has announced…
Reverb Therapeutics Raises $12M to Advance Amplify•R™ Platform
Reverb Therapeutics Raises $12M to Advance Amplify•R™ Platform Reverb Therapeutics, a biotechnology company pioneering innovative approaches to harness the natural immune system and cytokine signaling for the treatment of life-threatening…
PharmaJet to Showcase Advantages of Needle-Free Intradermal Delivery at Medical Conference in Ethiopia
PharmaJet to Showcase Advantages of Needle-Free Intradermal Delivery at Medical Conference in Ethiopia PharmaJet®, a company dedicated to enhancing the performance and outcomes of injectables through its innovative technology, has…
GeneDx Announces Q4 and Full-Year 2024 Financial Results and Provides 2025 Guidance
GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Guidance GeneDx Holdings Corp. (Nasdaq: WGS), a leader in leveraging genomic insights to drive improved health outcomes,…
Galderma’s Nemluvio® Approved in UK & Switzerland for Skin Conditions
Galderma’s Nemluvio® Approved in UK & Switzerland for Skin Conditions Galderma, a global leader in dermatology, has announced that its innovative monoclonal antibody treatment, Nemluvio® (nemolizumab), has been granted marketing…
ICC Arbitral Tribunal Decides in Favor of AOP Health in Arbitration over BESREMi® (Ropeginterferon alfa-2b)
ICC Arbitral Tribunal Decides in Favor of AOP Health in Arbitration over BESREMi® (Ropeginterferon alfa-2b) A tribunal under the International Chamber of Commerce (ICC) issued a partial final award in…